- Alkem Laboratories reported a net income of 6.64 billion rupees for the first quarter of 2025, exceeding estimates and showing a 22% year-on-year increase.
- The estimated net income was 5.11 billion rupees, making the company’s performance notably stronger than expected.
- Revenue for the quarter reached 33.7 billion rupees, which is an 11% increase compared to the previous year and above the estimated 32.33 billion rupees.
- Total costs amounted to 27.5 billion rupees, up by 8.7% from the prior year.
- Finance costs slightly rose to 297.8 million rupees, a 2.3% increase, exceeding the estimate of 272.5 million rupees.
- Employee benefits expenses increased by 15% year-on-year to 6.93 billion rupees, higher than the estimated 6.16 billion rupees.
- Alkem Laboratories reported other income of 1.36 billion rupees, marking a 13% increase compared to the previous year.
- The company’s shares experienced a 3.6% increase, reaching 5,021 rupees with 99,713 shares traded.
- Current investor sentiment on Alkem’s stock includes 9 buy recommendations, 7 hold recommendations, and 7 sell recommendations.
A look at Alkem Laboratories Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Alkem Laboratories Ltd, a pharmaceutical company, is positioned for a stable long-term outlook based on the Smartkarma Smart Scores. With a strong rating in resilience and dividends, Alkem shows promise in weathering market fluctuations and rewarding investors with consistent payouts. Additionally, its focus on growth highlights potential expansion opportunities in the pharmaceutical industry. While the value and momentum scores are slightly behind, the overall score reflects a well-rounded performance.
Alkem Laboratories Ltd‘s operations as a pharmaceutical company, researching, developing, and marketing generic and branded pharmaceuticals, along with nutraceuticals and herbal products, reflect a diversified product portfolio. This diversity, coupled with its solid scores in resilience and dividends, positions Alkem as a reliable player in the industry. The company’s strategic focus on innovation and market presence underscores its potential for sustained growth and continued success in the pharmaceutical market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
